New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
09:03 EDTRGDO, ISCA, NQ, AMGN, PCAR, LULU, BIND, APP, PETMOn The Fly: Pre-market Movers
HIGHER: PetSmart (PETM), up 16% after activist investor Jana Partners disclosed that it has acquired a 9.9% stake and intends to have talks with PetSmart’s board of directors and management regarding a review of strategic alternatives including exploring a sale... American Apparel (APP), up 9.6% after deposed CEO Dov Charney reportedly surrendered his entire stake and voting rights in the retailer to hedge fund Standard General, according to Reuters... International Speedway (ISCA), up 4% after reporting Q2 adjusted EPS and revenue that beat expectations... PACCAR (PCAR), up 4% after research reports said Daimler's (DDAIY) truck chief claimed to have been told that Volkswagen (VLKAY) wants to take over the truck maker, though a spokesman for Volkswagen told Dow Jones that there is "no truth" to the reports that it is planning an acquisition bid... lululemon (LULU), up 3.7% after The Wall Street Journal reported last night, citing people familiar with the situation, that the company's founder has been talking to private equity firms through advisers about taking the company private. LOWER: Regado Biosciences (RGDO), down 54% after announcing that the Data Safety Monitoring Board has initiated an unplanned review of data from the REGULATE-PCI trial and the stock was downgraded to Underperform from Outperform at Wedbush... NQ Mobile (NQ), down 21.5% after reporting that its auditor, PwC, has requested to expand the scope of its 2013 audit work and that the audit committee chair is stepping down from the board... BIND Therapeutics (BIND), down 13% after announcing Amgen (AMGN) will not be exercising its development option under the companies' collaborative research program.
News For PETM;LULU;NQ;APP;PCAR;ISCA;BIND;AMGN;RGDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 21, 2015
19:06 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:07 EDTAMGNAmgen shares higher by 2.69% after Q1 results, guidance
16:04 EDTAMGNAmgen raises FY15 EPS view to $9.35-$9.65 from $9.05-$9.40, consensus $9.32
Narrows FY15 revenue view to $20.9B-$21.3B from $20.8B-$21.3B, consensus $20.98B.
16:02 EDTAMGNAmgen reports Q1 EPS $2.48, consensus $2.10
Reports Q1 revenue $5.03B, consensus $4.91B.
15:28 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:51 EDTAMGNEarnings Watch: Amgen's Enbrel, Neulasta sales key for Q1 results
Amgen (AMGN) is scheduled to report first quarter earnings after the market close on Tuesday, April 21 with a conference call scheduled for 5:00 pm ET. Amgen, a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases. EXPECTATIONS: Analysts are looking for earnings per share of $2.10 on revenue of $4.91B, according to First Call. The consensus range for EPS is $1.91-$2.25 on revenue of $4.62B-$5.13B. LAST QUARTER: Amgen reported fourth quarter EPS of $2.16 against estimates of $2.05 on revenue of $5.33B against estimates of $5.2B. With its Q4 report, Amgen also reiterated its fiscal year EPS view of 9.05-$9.40, on revenue of of $20.8B-$21.3B. Total product sales increased 8% for Q4 versus Q4 of 2013. The increase was driven primarily by Enbrel, Neulasta, Prolia, XGEVA and Vectibix .Growth for the quarter was due primarily to higher unit demand, and to a lesser extent, price. Product sales increased 6% for the full year driven by strong performance across the portfolio. STREET RESEARCH: On March 23, Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen, Eli Lilly (LLY), and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares. On March 16, RBC Capital said it believes that data presented by Amgen on its evolocumab drug for hyperlipidemia.was "very positive." The firm expects the drug to be approved in late summer. It predicts that revenue from the drug will ramp modestly and steadily, and then accelerate after positive studies of the drug's effects are released in 2017. RBC Capital estimates that worldwide revenue from the drug will peak at $2.5B+. It keeps an Outperform rating on Amgen. PRICE ACTION: Amgen shares are higher by around 6% since its last earnings report on January 27, and are up 1.25% to to $168.06 in afternoon trading ahead of Tuesday's earnings report.
09:14 EDTNQNQ Mobile to hold a conference call
Conference call to discuss changes to the company's management team and management structure will be held on April 21 at 9 am. Webcast Link
08:11 EDTNQNQ Mobile announces co-CEO Omar Khan to transition to advisory role
NQ Mobile announced that Omar Khan, current Co-CEO of NQ Mobile, has decided to transition to an advisory role and step down in his capacity as Co-CEO and director of the company, effective as of May 1, 2015. At the same time, Khan will also resign from his position as the CEO of NQ Mobile US, a direct wholly owned subsidiary of the company, and from his other roles within the company. To help with a smooth transition, Khan will remain with the company as an advisor through December 31, 2015. As part of this transition, in order to streamline the management process of the company, the company will also eliminate the Co-CEO management structure. The board has decided to appoint Zemin Xu, the current Co-CEO of the company, to take over as the company's CEO, effective as of May 1, 2015.
08:02 EDTPCARPACCAR says DAF 'cooperating' with European Commission
DAF is cooperating with the European Commission and is preparing its response to the Statement of Objections issued in November 2014. The Statement expressed the Commission’s preliminary view that all major European medium- and heavy-duty truck manufacturers had participated in anticompetitive practices in the European Union. The Commission indicated that it will seek to impose significant fines on the manufacturers. The Commission will review the manufacturers’ responses before issuing a decision. Any decision would be subject to appeal. The Company is unable to estimate the potential fine at this time.
08:02 EDTPCARPACCAR reports Q1 EPS $1.06, consensus $1.01
Subscribe for More Information
April 20, 2015
15:37 EDTPCARNotable companies reporting before tomorrow's open
Subscribe for More Information
10:00 EDTLULUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:55 EDTLULUlululemon downgraded at CLSA
As previously reported, CLSA downgraded lululemon to Underperform from Outperform. The firm downgraded shares due to valuation and maintained its $68 price target.
07:21 EDTLULU, LULUlululemon downgraded to Underperform from Outperform at CLSA
Subscribe for More Information
April 19, 2015
12:41 EDTPCARKroger, Dollar General, others can be bought and held for 3 years, Barron's says
Shares of PACCAR (PCAR), Lam Research (LRCX), Kroger (KR), Autoliv (ALV), Archer Daniels (ADM), and Dollar General (DG) should be bought and held for the next three years due to high return on invested capital, Barron's contends in a feature article. Reference Link
April 17, 2015
09:20 EDTAMGNInsulet weakness creates buying opportunity, says Wedbush
Wedbush believes that Insulet's growth should accelerate as the year progresses, driven by increased adoption of its unique, programmable insulin pump and the launch of Amgen's (AMGN) Neulasta On-Body Delivery System.
April 16, 2015
11:52 EDTAPPAmerican Apparel factory workers file new complaints to Labor Board, WWD reports
American Apparel factory workers may be close to formally organizing after four new grievances filed with the National Labor Relations Board, reports WWD. The complaints all cite varying violations of the National Labor Relations Act, alleging that American Apparel interfered with workers' rights to talk with union organizers. Reference Link
April 15, 2015
18:56 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:06 EDTAMGNAmgen confirms FDA approval of Corlanor
Subscribe for More Information
16:40 EDTAMGNFDA approves Amgen's Corlanor to treat heart failure
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use